Martin R. Brown

Martin R. Brown is the CEO of Ambra BioScience. Martin has over 25 years of experience in the pharmaceutical and biotechnology industry, including co-founding Elcelyx Therapeutics Inc. and serving as Senior Vice President at Amylin Pharmaceuticals.

Martin began their career in 1994 at Amylin Pharmaceuticals as Senior Director of IT. Martin was quickly promoted to VP of Operations in 1998, where they oversaw HR, IT, Facilities, Procurement, Project Management, Product Development, and Finance. In 2000, Amylin had disappointing clinical results which led to a downsizing from 300 employees to just 36. However, by the end of that year, positive clinical results had spurred a rebound to over 100 employees and raised over $100 million.

From 2000 to 2005, Martin helped Amylin transition from a development stage company to a commercial stage company. They launched Byetta and Symlin, two first-in-class diabetes drugs, and inked a deal with Lilly to market Byetta. By 2005, Amylin had grown to 1100 employees.

In 2010, Martin came out of retirement to co-found Elcelyx Therapeutics specifically to develop the science of GSM (glycosylation sequence modification). Elcelyx advanced two GSM-based programs: one was a non-Rx program for weight loss (which was subsequently acquired by Ambra), and the other was an Rx program for Type 2 diabetes.

Martin is now using their wealth of experience to lead Ambra BioScience as its CEO.

Martin R. Brown graduated with a BS/MBA in Operations Research and Management from Drexel University's LeBow College of Business.

Some direct reports include Tamara S. Sofi - Channel Strategist, Mark J. Tager - MD, Medical Communication, and Clegg Hubbell - COO.